|
|
Prepublished online as a Blood First Edition Paper on May 15, 2003; DOI 10.1182/blood-2003-01-0190.

Submitted January 22, 2003
Accepted May 7, 2003
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity
Cecilia Melani*, Claudia Chiodoni, Guido Forni, and Mario P Colombo
Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
* Corresponding author; email: melani{at}istitutotumori.mi.it.
Transgenic female mice expressing the transforming rat oncogene c-erbB-2 (HER-2/neu) under the MMTV promoter (BALB-neuT) spontaneously develop mammary carcinomas with a progression resembling that of human breast cancer. In these mice activating anti-tumor immunotherapy fails to induce T cell-mediated cytotoxicity, suggesting a suppression of the immune response. We found a direct correlation between tumor multiplicity and an increased proportion of Gr-1/Mac-1/ER-MP12-positive immature myeloid cells in the peripheral blood (PB) and spleen, suggesting that tumor load profoundly affects overall BALB-neuT hemopoiesis. In fact, myeloid colony formation was increased in bone marrow (BM) and spleen. The immature myeloid cells displayed suppressive activity on host T lymphocytes, which progressively failed to respond to allo-antigens and CD3 triggering, while maintaining the ability to proliferate in response to non-specific mitogens. Transplantation of normal BM into BALB-neuT mice readily resulted in hypertrophic hemopoiesis with myeloid cell expansion. This persistent influence of the tumor was mediated through the release of VEGF but not GM-CSF, and was down-modulated when tumor load was reduced but not when BM was transplanted. Together, the data obtained in the BALB-neuT model of naturally occurring carcinogenesis show that tumor-associated immune suppression is secondary to a more general alteration of host hemopoiesis, conditioned by tumor-secreted soluble factors.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. C. McKenna, K. M. Beatty, R. A. Bilonick, L. Schoenfield, K. L. Lathrop, and A. D. Singh
Activated CD11b+ CD15+ Granulocytes Increase in the Blood of Patients with Uveal Melanoma
Invest. Ophthalmol. Vis. Sci.,
September 1, 2009;
50(9):
4295 - 4303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ilkovitch and D. M. Lopez
The Liver Is a Site for Tumor-Induced Myeloid-Derived Suppressor Cell Accumulation and Immunosuppression
Cancer Res.,
July 1, 2009;
69(13):
5514 - 5521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Stewart, D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams
Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells
J. Immunol.,
July 1, 2009;
183(1):
117 - 128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Norian, P. C. Rodriguez, L. A. O'Mara, J. Zabaleta, A. C. Ochoa, M. Cella, and P. M. Allen
Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism
Cancer Res.,
April 1, 2009;
69(7):
3086 - 3094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Mailloux and M. R. I. Young
NK-Dependent Increases in CCL22 Secretion Selectively Recruits Regulatory T Cells to the Tumor Microenvironment
J. Immunol.,
March 1, 2009;
182(5):
2753 - 2765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al.
Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9
Clin. Cancer Res.,
March 1, 2009;
15(5):
1575 - 1584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev, Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kubler, D. Yancey, P. Dahm, and J. Vieweg
Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
Clin. Cancer Res.,
December 15, 2008;
14(24):
8270 - 8278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Nausch, I. E. Galani, E. Schlecker, and A. Cerwenka
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells
Blood,
November 15, 2008;
112(10):
4080 - 4089.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
J. Immunol.,
October 15, 2008;
181(8):
5791 - 5802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Re and J. L. Cook
The physiological basis of intracrine stem cell regulation
Am J Physiol Heart Circ Physiol,
August 1, 2008;
295(2):
H447 - H453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Willimsky, M. Czeh, C. Loddenkemper, J. Gellermann, K. Schmidt, P. Wust, H. Stein, and T. Blankenstein
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
J. Exp. Med.,
July 7, 2008;
205(7):
1687 - 1700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kobayashi, T. Yoshida, D. Takeuchi, V. C. Jones, K. Shigematsu, D. N. Herndon, and F. Suzuki
Gr-1+CD11b+ cells as an accelerator of sepsis stemming from Pseudomonas aeruginosa wound infection in thermally injured mice
J. Leukoc. Biol.,
June 1, 2008;
83(6):
1354 - 1362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Movahedi, M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Blood,
April 15, 2008;
111(8):
4233 - 4244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili
Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors
Cancer Res.,
April 1, 2008;
68(7):
2436 - 2446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wels, R. N. Kaplan, S. Rafii, and D. Lyden
Migratory neighbors and distant invaders: tumor-associated niche cells
Genes & Dev.,
March 1, 2008;
22(5):
559 - 574.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Levchenko, N. Veitonmaki, A. Lundkvist, H. Gerhardt, Y. Ming, K. Berggren, A. Kvanta, R. Carlsson, and L. Holmgren
Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo
FASEB J,
March 1, 2008;
22(3):
880 - 889.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S.-H. Chen
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
Blood,
January 1, 2008;
111(1):
219 - 228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo
Amino-Biphosphonate Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma
Cancer Res.,
December 1, 2007;
67(23):
11438 - 11446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg
Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression
Cancer Res.,
October 15, 2007;
67(20):
10019 - 10026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Talmadge
Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5243 - 5248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Celis
Toll-like Receptor Ligands Energize Peptide Vaccines through Multiple Paths
Cancer Res.,
September 1, 2007;
67(17):
7945 - 7947.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Ko, Y.-J. Kim, Y.-S. Kim, W.-S. Chang, S.-Y. Ko, S.-Y. Chang, S. Sakaguchi, and C.-Y. Kang
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
Cancer Res.,
August 1, 2007;
67(15):
7477 - 7486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg
Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response
J. Immunol.,
July 15, 2007;
179(2):
977 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Spadaro, C. Curcio, A. Varadhachary, F. Cavallo, J. Engelmayer, P. Blezinger, F. Pericle, and G. Forni
Requirement for IFN-{gamma}, CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors
Cancer Res.,
July 1, 2007;
67(13):
6425 - 6432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yu, C. Liu, K. Su, J. Wang, Y. Liu, L. Zhang, C. Li, Y. Cong, R. Kimberly, W. E. Grizzle, et al.
Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells
J. Immunol.,
June 1, 2007;
178(11):
6867 - 6875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis
Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors
Cancer Res.,
February 1, 2007;
67(3):
1326 - 1334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G Parmiani, C Castelli, L Pilla, M Santinami, M. Colombo, and L Rivoltini
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Ann. Onc.,
February 1, 2007;
18(2):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rolla, C. Nicolo, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria
Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice
J. Immunol.,
December 1, 2006;
177(11):
7626 - 7633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Chiodoni, M. Iezzi, C. Guiducci, S. Sangaletti, I. Alessandrini, C. Ratti, F. Tiboni, P. Musiani, D. N. Granger, and M. P. Colombo
Triggering CD40 on endothelial cells contributes to tumor growth
J. Exp. Med.,
October 30, 2006;
203(11):
2441 - 2450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients.
Cancer Res.,
September 15, 2006;
66(18):
9299 - 9307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ambrosino, M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W.-Z. Wei, and F. Cavallo
Immunosurveillance of erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.
Cancer Res.,
August 1, 2006;
66(15):
7734 - 7740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Van Ginderachter, S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G. Hassanzadeh Ghassabeh, G. Raes, and P. De Baetselier
Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer
Blood,
July 15, 2006;
108(2):
525 - 535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Yang, Z. Cai, Y. Zhang, W. H. Yutzy IV, K. F. Roby, and R. B.S. Roden
CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells.
Cancer Res.,
July 1, 2006;
66(13):
6807 - 6815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Song, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte
CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1{beta}-Secreting Cells
J. Immunol.,
December 15, 2005;
175(12):
8200 - 8208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev, S. Nagaraj, and D. I. Gabrilovich
Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
J. Immunol.,
October 1, 2005;
175(7):
4583 - 4592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Larrivee, I. Pollet, and A. Karsan
Activation of Vascular Endothelial Growth Factor Receptor-2 in Bone Marrow Leads to Accumulation of Myeloid Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor
J. Immunol.,
September 1, 2005;
175(5):
3015 - 3024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev and D. I. Gabrilovich
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
J. Immunol.,
April 15, 2005;
174(8):
4880 - 4891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Zehntner, C. Brickman, L. Bourbonniere, L. Remington, M. Caruso, and T. Owens
Neutrophils That Infiltrate the Central Nervous System Regulate T Cell Responses
J. Immunol.,
April 15, 2005;
174(8):
5124 - 5131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. De Santo, P. Serafini, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M. P. Colombo, M. Iezzi, et al.
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination
PNAS,
March 15, 2005;
102(11):
4185 - 4190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello
High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
Cancer Res.,
September 1, 2004;
64(17):
6337 - 6343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Dring, F. E. Davies, J. A. L. Fenton, P. L. Roddam, K. Scott, D. Gonzalez, S. Rollinson, A. C. Rawstron, K. S. Rees-Unwin, C. Li, et al.
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma
Clin. Cancer Res.,
September 1, 2004;
10(17):
5692 - 5701.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|